title: Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates.
abstract: Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates. Our objective was to analyze the influence of FDPS polymorphisms on bone mineral density (BMD) and the response to antiresortive drugs. Three single-nucleotide polymorphisms of FDPS were analyzed in 1186 postmenopausal women. There was only a marginally significant association of baseline hip BMD with rs11264359 alleles (P=0.043). However, among 191 women receiving antiresortive therapy, there was a very significant association between rs2297480 or rs11264359 alleles and the BMD changes after aminobisphosphonate therapy for an average period of 2.5 years (P=0.001). The genotype explained 7.2% of the variance in the BMD response. On the other hand, there was no association between the BMD changes after raloxifene therapy and any of the polymorphisms studied. These results suggest that common polymorphisms of the FDPS gene influence the response to aminobisphosphonates.
authors.affiliation: Department of Internal Medicine, Hospital UM Valdecilla-IFIMAV, University of Cantabria, Santander, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Olmos
authors.forename: M T
authors.initials: MT
authors.lastname: Zarrabeitia
authors.forename: J L
authors.initials: JL
authors.lastname: Hernández
authors.forename: C
authors.initials: C
authors.lastname: Sañudo
authors.forename: J
authors.initials: J
authors.lastname: González-Macías
authors.forename: J A
authors.initials: JA
authors.lastname: Riancho
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D015519:Bone Density / Q000187:drug effects / Q000235:genetics; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005787:Gene Frequency; D051228:Geranyltranstransferase / Q000235:genetics* / Q000378:metabolism; D006239:Haplotypes; D006801:Humans; D016014:Linear Models; D015810:Linkage Disequilibrium; D008875:Middle Aged; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D018570:Risk Assessment; D012307:Risk Factors; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D051228:Geranyltranstransferase